[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 330 4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 59, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 66, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 591875, "exercisedValue": 0, "unexercisedValue": 116098}, {"maxAge": 1, "name": "Mr. Axel  Bolte M.B.A., M.Sc.", "age": 52, "title": "Co-Founder, Senior Advisor & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1158083, "exercisedValue": 0, "unexercisedValue": 1257688}, {"maxAge": 1, "name": "Mr. Sanjay S. Subramanian M.B.A., M.S.", "age": 47, "title": "Senior VP, CFO, Principal Accounting Officer & Corporate Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 626233, "exercisedValue": 0, "unexercisedValue": 47925}, {"maxAge": 1, "name": "Dr. Matthew  Winton Ph.D.", "age": 46, "title": "Senior VP & COO", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 526431, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Demetrios  Braddock M.D., Ph.D.", "title": "Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Soojin  Kim Ph.D.", "title": "Senior VP & Chief Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Riley", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gayle  Gironda", "title": "Senior VP & Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yves  Sabbagh Ph.D.", "title": "Chairman of Scientific Advisory Board & Senior VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Di Palma M.B.A.", "age": 65, "title": "Consultant", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.35, "open": 1.37, "dayLow": 1.33, "dayHigh": 1.4284, "regularMarketPreviousClose": 1.35, "regularMarketOpen": 1.37, "regularMarketDayLow": 1.33, "regularMarketDayHigh": 1.4284, "beta": 1.287, "forwardPE": -0.91333336, "volume": 416037, "regularMarketVolume": 416037, "averageVolume": 816006, "averageVolume10days": 617860, "averageDailyVolume10Day": 617860, "bid": 1.34, "ask": 1.41, "bidSize": 600, "askSize": 400, "marketCap": 88009072, "fiftyTwoWeekLow": 1.235, "fiftyTwoWeekHigh": 7.795, "fiftyDayAverage": 2.1755, "twoHundredDayAverage": 4.1175, "currency": "USD", "enterpriseValue": 3193071, "floatShares": 32591622, "sharesOutstanding": 64240200, "sharesShort": 3658387, "sharesShortPriorMonth": 3701002, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.056900002, "heldPercentInsiders": 0.013099999, "heldPercentInstitutions": 0.92500997, "shortRatio": 3.66, "shortPercentOfFloat": 0.0616, "impliedSharesOutstanding": 66455400, "bookValue": 1.29, "priceToBook": 1.0620155, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -96494000, "trailingEps": -1.55, "forwardEps": -1.62, "enterpriseToEbitda": -0.032, "52WeekChange": -0.766436, "SandP52WeekChange": 0.22903383, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "INZY", "underlyingSymbol": "INZY", "shortName": "Inozyme Pharma, Inc.", "longName": "Inozyme Pharma, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f627b06e-ce15-3126-896c-1db8a4222086", "messageBoardId": "finmb_568596329", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.37, "targetHighPrice": 30.0, "targetLowPrice": 11.0, "targetMeanPrice": 18.0, "targetMedianPrice": 15.5, "recommendationKey": "none", "numberOfAnalystOpinions": 8, "totalCash": 131608000, "totalCashPerShare": 2.049, "ebitda": -98893000, "totalDebt": 46792000, "quickRatio": 7.174, "currentRatio": 7.683, "debtToEquity": 56.52, "returnOnAssets": -0.35691002, "returnOnEquity": -0.79419, "freeCashflow": -55929500, "operatingCashflow": -91206000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]